Miniatura

Fitxers

12474_5651482_dipasquale2018.pdf (636.05 KB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2018-08-23

Tots els drets reservats

Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/136778

Prevalence and Etiology of Community-acquired Pneumonia in Immunocompromised Patients

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://dx.doi/10.1093/cid/ciy723

Resum

Background: The correct management of immunocompromised patients with pneumonia is debated. We evaluated the prevalence, risk factors, and characteristics of immunocompromised patients coming from the community with pneumonia. Methods: We conducted a secondary analysis of an international, multicenter study enrolling adult patients coming from the community with pneumonia and hospitalized in 222 hospitals in 54 countries worldwide. Risk factors for immunocompromise included AIDS, aplastic anemia, asplenia, hematological cancer, chemotherapy, neutropenia, biological drug use, lung transplantation, chronic steroid use, and solid tumor. Results: At least 1 risk factor for immunocompromise was recorded in 18% of the 3702 patients enrolled. The prevalences of risk factors significantly differed across continents and countries, with chronic steroid use (45%), hematological cancer (25%), and chemotherapy (22%) the most common. Among immunocompromised patients, community-acquired pneumonia (CAP) pathogens were the most frequently identified, and prevalences did not differ from those in immunocompetent patients. Risk factors for immunocompromise were independently associated with neither Pseudomonas aeruginosa nor non–community-acquired bacteria. Specific risk factors were independently associated with fungal infections (odds ratio for AIDS and hematological cancer, 15.10 and 4.65, respectively; both P = .001), mycobacterial infections (AIDS; P = .006), and viral infections other than influenza (hematological cancer, 5.49; P < .001). Conclusions: Our findings could be considered by clinicians in prescribing empiric antibiotic therapy for CAP in immunocompromised patients. Patients with AIDS and hematological cancer admitted with CAP may have higher prevalences of fungi, mycobacteria, and noninfluenza viruses.

Matèries

Pneumònia adquirida a la comunitat, Etiologia

Matèries (anglès)

Community-acquired pneumonia, Etiology

Citació

Col·leccions

Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)

Citació

PASQUALE, Marta francesca di, SOTGIU, Giovanni, GRAMEGNA, Andrea, RADOVANOVIC, Dejan, TERRANEO, Silvia, REYES, Luis f., RUPP, Jan, GONZÁLEZ DEL CASTILLO, Juan, BLASI, Francesco, ALIBERTI, Stefano, RESTREPO, Marcos i., CILLÓNIZ, Catia, TORRES MARTÍ, Antoni, GLIMP Investigators. Prevalence and Etiology of Community-acquired Pneumonia in Immunocompromised Patients. _Clinical Infectious Diseases_. 2019. Vol. 68, núm. 9, pàgs. 1482-1493. [consulta: 20 de gener de 2026]. ISSN: 1537-6591. [Disponible a: https://hdl.handle.net/2445/136778]

Exportar metadades

JSON - METS

Compartir registre